Pharmalot… Pharmalittle… Good Morning

Hello, everyone, and how are you this morning? The sun is shining brightly here on the Pharmalot corporate campus, where the short people and the official mascots are snoozing happily. As for us, we are rifling through documents and other reading matter in search of interesting stories to pass along. As always, there is much to do. We know you relate, so please join us for a mandatory cup of stimulation. No one should do without. Meanwhile, here are some tidbits. Hope your day goes well and drop us a line if something fascinating occurs… New Consumer Advocates To Join FDA Panels (Regulatory Focus) Shire CEO Eyes Two Or More Acquisitions (Bloomberg News) Sanofi Does Not Owe Tax On Shanta Deal (PharmaBiz) FDA Rejection Of Novo Insulin Is Temporary But Costly (Reuters) China Issues New Quality Standards For Drug Distribution (Xinhua) Merck And Samsung To Develop Biosimilars (Associated Press) Chelsea To Resubmit Orthostatic Hypotension Drug To FDA (Pharma Times) Five Interesting Things From The Quintiles IPO Filing (MedCity News) Clinical Trial Regs Hinder Pediatric Cancer Progress (Pharma Times) No IBD Risk Seen With Acne Drug (MedPage Today) EDITOR’S NOTE: Please check this post for additional items during the day
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Biosimilars Chelsea Therapeutics Clinical Trials FDA Insulin Merck Novo Nordisk Orthostatic Hypotension Quintiles Samsung Sanofi Shire Source Type: blogs